Booting Earth Optimization System
Thank you for your patience. Your civilization is very important to us.
Loteprednol etabonate ophthalmic suspension (short-term)
Treatment for Dry Eye Disease
Typical Dosage: One drop 2-4 times daily, then taper
Effectiveness
75%
Safety Score
65%
Clinical Trials
60
Participants
9K
Comparative Safety Scale(Higher is safer)
Cyanide☠️
Meth💀
Cigarettes🚬
Chemo☢️
Alcohol🍺
Morphine💊
Antibiotics💉
Tylenol💊
Exercise🏃
Water💧
65
DangerousModerateSafe
Treatment Details
Dosage Range
One drop 2-4 times daily, then taper
Time to Effect
Days to 1 week
Treatment Duration
2-4 weeks (pulsed therapy)
Evidence Quality
HIGHNumber Needed to Treat (NNT)
3(Treat 3 patients to see 1 additional successful outcome)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$250
Monitoring:$50
Side Effect Mgmt:$20
Total Annual:$320
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
0.02
Outcome-Based Costs
Cost per Responder
$427
Loteprednol etabonate ophthalmic suspension (short-term) Outcomes
for Dry Eye Disease
Efficacy Outcomes
Overall Effectiveness
+75%
Response Rate
+75%
Common Side Effects
Ocular pain/stinging
+10%
Blurred vision
+5%
Transient increase in IOP (low risk with short-term use)
+1%
Sources:
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov